Newlands E S, Oon C J, Roberts J T, Elliott P, Mould R F, Topham C, Madden F J, Newton K A, Westbury G
Br J Cancer. 1976 Aug;34(2):174-9. doi: 10.1038/bjc.1976.140.
Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated allogeneic melanoma cells mixed with 50 mug of percutaneous BCG. The survival rates in both treatment groups C and (C+I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C+I) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.
56例播散性恶性黑色素瘤患者被随机分为两个治疗组。第一组C接受由达卡巴嗪（DTIC）和丙亚胺（ICRF 159）组成的联合化疗。第二组（C + I）接受相同的化疗，但同时用2×10⁷经照射的同种异体黑色素瘤细胞与50微克经皮卡介苗混合进行免疫。治疗组C和（C + I）的生存率无显著差异，且在（C + I）组仅发现化疗有轻微增强。两组观察到相似的组织反应模式：淋巴结、皮肤以及在一定程度上肝转移灶的反应优于其他部位。
